Navigation Links
Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer
Date:9/10/2009

HORSHAM, Pa., Sept. 10 /PRNewswire/ -- Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection) in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer.

Centocor Ortho Biotech is evaluating the FDA's letter and will respond to the agency as quickly as possible.

The sNDA for DOXIL was submitted to the FDA in September 2008. DOXIL currently is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after prior platinum-based therapy. DOXIL in combination with bortezomib is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy. DOXIL is also indicated for the treatment of AIDS-related Kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy.

DOXIL is marketed in the United States by Centocor Ortho Biotech Products, L.P., and in Israel by Janssen-Cilag. Schering-Plough Corporation, under a licensing agreement, has exclusive rights to market the medication as CAELYX throughout the rest of the world, excluding Japan and Israel. For more information about DOXIL, please visit www.DOXIL.com.

IMPORTANT SAFETY INFORMATION

BOXED WARNINGS:

Cardiotoxicity, infusion reaction, myelosuppression, liver impairment, substitution

  • The use of DOXIL may lead to cardiac toxicity. Myocardial damage may lead to congestive heart failure and may occur as the total cumulative do
    '/>"/>

SOURCE Centocor Ortho Biotech Products, L.P.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
2. Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
3. Centocor/Janssen-Cilags Ustekinumab Will Become the Gold Standard for Psoriasis By 2011
4. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
5. Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product
6. GeneNews provides Centocor access to its osteoarthritis program
7. Baseline Research Indicates High Interest in Centocor-Ortho Biotechs SIMPONI(R)
8. Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
9. Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories
10. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
11. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... , ... CSM, a leading clinical trial supply company, today announced that Michael ... extensive background in financial management and accounting, bringing over 20 years of experience in ... will oversee all financial areas of the company to both strengthen CSM’s financial strategy ...
(Date:7/6/2015)... ... July 06, 2015 , ... A study ... insights into how virulent fungi adapt through genetic modifications to fight back against ... leaves them temporarily weakened. These insights may provide clues to new ways to ...
(Date:7/6/2015)... Wellesley, Mass. (PRWEB) , ... July 06, 2015 ... ... development of simpler and cheaper molecular diagnostic tests are key drivers of the ... projected growth of personalized medicine and the introduction of new companion diagnostic tests ...
(Date:7/6/2015)... -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today ... Clinical (Novella), to conduct the phase 3 registration ... Novella is a full-service, global clinical research organization (CRO) ... companies. The ICT-107 phase 3 trial will include approximately ... and Canada , and ...
Breaking Biology Technology:CSM Appoints Michael Morse as Vice President of Finance 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 4Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 2Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 3ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2
... on a poultry farm in Texas. Soon, there are reports ... and New Jersey. How can health officials be mobilized to ... humans? , ,That process may well begin at the All-Emergency ... Services Secretary Tommy Thompson to keep tabs on the range ...
... , today announced the addition of two new members ... Weis. , ,The Madison-based media communications company hopes to ... its board of directors with the appointments. Peercy and ... meeting, at which time they will stand for election. ...
... intranets are frustrated. In a recent Moreover survey, 58 ... information resource at work, but only 11 percent considered ... Given all the money and effort that has gone ... value in them? , ,By 1998, companies were already ...
Cached Biology Technology:Federal command center is at the front line of defense for public health emergencies 2Federal command center is at the front line of defense for public health emergencies 3The unfilled promise of corporate intranets 2The unfilled promise of corporate intranets 3
(Date:6/12/2015)... 12, 2015  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announced the ... electronically capture, analyze and identify participants of a ... This system can: , ... and subsequent sign-on process is actually the person ...
(Date:6/10/2015)... 10, 2015 According to ... by Technology (Ultrasound, TOF, Structured Light, Stereo Vision), ... Automotive) and by Geography - Trends & Forecast ... market is expected to reach $3,319.71 Million by ... 2015 and 2020. Browse 71 market ...
(Date:6/9/2015)... DUBLIN , June 09, 2015 ... the addition of the "Gesture Recognition & ... Application (Consumer Electronics, Automotive, & Others), Product (Biometric ... Forecast to 2020" report to their offering. ... sensing market is expected to reach $ 23.55 ...
Breaking Biology News(10 mins):Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 23D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... of folic acid around the time of conception and throughout ... one day deserve a spot on the obstetrician,s list of ... choline a nutrient found in eggs and meat ... such as mental health disturbances, and chronic conditions, like hypertension, ...
... floating islands containing papyrus plants to help protect the ... Kenya. The German REWE Group is funding a ... grower Finlays and Dr David Harper, a Senior Lecturer ... the water-cleansing services of papyrus as artificial floating islands. ...
... Sept. 20, 2012 Novetta Solutions, LLC (Novetta), ... announced the acquisition of International Biometric Group, LLC ... to customers within the National Security community and ... Novetta was established in March 2012 through the ...
Cached Biology News:Nutrient in eggs and meat may influence gene expression from infancy to adulthood 2Nutrient in eggs and meat may influence gene expression from infancy to adulthood 3Novel plastic-and-papyrus restoration project 2Novel plastic-and-papyrus restoration project 3Novetta Solutions Acquires International Biometric Group, LLC 2Novetta Solutions Acquires International Biometric Group, LLC 3
Homo sapiens postsynaptic protein CRIPT Antigen: Recombinant Protein...
... quadrupole 1200L sets the new standard ... - incorporating the latest technologies and ... chromatography analytical needs. The Atmospheric ... Transmission Quadrupole Analyzer provide superior selectivity ...
Human Legumain Affinity Purified Polyclonal Ab...
Mouse Endoglin/CD105 Fluorescein MAb (Clone 209701)...
Biology Products: